Cosmetic cross-reference Noindex: medium evidence

99-56-9

CAS 99-56-9

99-56-9 (CAS 99-56-9) is a pharmaceutical compound with 1 bioactivity target and 0 adverse event associations.

SOURCE NLM DailyMed
Label records
0
SOURCE EMBL-EBI ChEMBL
Bioactivity
1
SOURCE DrugCentral
Adverse signals
0
SOURCE IUPHAR/BPS
PubMed IDs
0
SOURCE EMBL-EBI ChEMBL B25820EEF0F0

Compound Identity

Matched identifiers and naming fields for the pharmaceutical compound record.

Primary Name
99-56-9
CAS Number
99-56-9
UNII
5A9AX7Y0TT
InChIKey
RAUWPNXIALNKQM-UHFFFAOYSA-N
ChEMBL ID
CHEMBL433721
Molecule Type
Small molecule
Source Match
EMBL-EBI ChEMBL (INCHIKEY)
SOURCE Ingredients table / CosIng profile same-CAS cross-reference

Cross-Reference to Cosmetics

Same-CAS ingredient record found in the cosmetics vertical.

SOURCE EMBL-EBI ChEMBL 1 bioactivity row

Bioactivity & Target Interactions

Target-level activity records with assay counts, activity type, and measured value where present.

TargetActivity ValueAssaysOrganism
- Potency 25255.60625 nM 13 -
SOURCE Rendered pharma page rows FAQPage JSON-LD

Frequently Asked Questions

Short answers generated only from the same visible source-linked rows on this page.

What is 99-56-9 used for in pharmaceutical contexts?

99-56-9 (CAS 99-56-9) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.

What are the known adverse events for 99-56-9?

No adverse-event association or SIDER side-effect rows are rendered for 99-56-9 in this page query. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.

Is 99-56-9 also used in cosmetics?

Yes. The ingredients table has a same-CAS cosmetic profile for 4-Nitro-O-Phenylenediamine with EU status "restricted".

What clinical phase is 99-56-9 in?

No phase 1-4 clinical development badge is rendered for 99-56-9 because the matched compound identifier rows do not contain a max-phase value.